指南与共识乳腺乳腺X线US

2026美国乳腺非典型病变与LCIS管理指南

American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 Guidelines for the Management of Proliferative Lesions With Atypia and Lobular Carcinoma In Situ.
指南 / 共识 · JAMA Surg · 2026-01-01

美国乳腺外科医师学会联合乳腺影像学会及美国病理学会制定指南,涵盖FEA、ADH、ALH、C-LCIS、P-LCIS及F-LCIS管理。ADH、ALH、C-LCIS提示未来乳腺癌风险升高,应推荐全面风险评估与降低风险咨询。多数空心针活检诊断的ADH、P-LCIS及F-LCIS需诊断性切除,ALH和C-LCIS在影像-病理一致时可安全观察。

要点

  • ALH和C-LCIS在空心针活检诊断与影像特征一致时可安全观察,不必常规切除。
  • P-LCIS与F-LCIS需切缘阴性;ADH不需要切缘阴性。
  • 单独诊断FEA且影像-病理一致时通常不需要诊断性切除。

核心结论

  • 该指南为乳腺非典型病变及LCIS提供了基于证据与共识的管理推荐,涵盖ADH、ALH、FEA、C-LCIS、P-LCIS和F-LCIS。
  • ADH、ALH和C-LCIS患者应推荐接受全面风险评估及降低乳腺癌风险策略咨询。
  • 空心针活检诊断的大多数ADH、P-LCIS和F-LCIS需诊断性切除,部分符合严格标准且多学科共识的ADH病例可观察。

研究设计与样本

  • 美国乳腺外科医师学会联合乳腺影像学会及美国病理学会组建指导组制定指南。
  • 指南纳入扁平上皮非典型性、非典型导管增生、非典型小叶增生、经典型LCIS、多形性LCIS及旺炽型LCIS。
  • 原文未报告指南制定的系统检索数据库、检索时间范围及证据分级方法的具体细节。

关键影像表现/征象

  • 空心针活检诊断病变后需判断影像-病理一致性,即活检诊断与影像特征是否相符。

诊断标准与关键数值

  • 推荐对ADH进行第二次病理复核确认;对FEA应考虑第二次病理复核;对ALH或LCIS无必要行第二次病理复核。
  • P-LCIS和F-LCIS需切缘阴性;ADH不需要切缘阴性。
  • 部分ADH病例需满足严格标准并经多学科共识方可选择观察而非切除。
  • 若P-LCIS和F-LCIS确定为激素受体阳性,应考虑使用降低风险药物。

临床应用与阅片要点

  • 报告ADH时应建议第二次病理复核并考虑诊断性切除,少数符合严格标准且多学科共识者可观察。
  • 报告ALH或C-LCIS时,若空心针活检诊断与影像特征一致,可安全观察而无需常规切除。
  • 报告单独FEA且影像-病理一致性确认后,通常不建议诊断性切除。
  • 报告P-LCIS或F-LCIS时需提示切缘阴性要求,并在激素受体阳性时考虑降低风险药物。
  • 日常阅片应重点确认空心针活检诊断与影像特征是否一致,以决定是否可安全观察。

局限性

  • P-LCIS和F-LCIS相关的未来乳腺癌风险程度仍不明确。
  • 原文未提供诊断性切除或观察策略所依据的敏感度、特异度、AUC或样本量等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

IMPORTANCE: Many patients are diagnosed with atypical lesions or lobular carcinoma in situ (LCIS); however, evidence- and consensus-based guidelines for the management of many of these lesions are limited.

OBSERVATIONS: The American Society of Breast Surgeons, in collaboration with the Society of Breast Imaging and College of American Pathology, assembled a steering group to create guidelines for the management of atypical lesions and LCIS, inclusive of flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), classic LCIS (C-LCIS), and the variant LCIS forms pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS). The natural history of ADH, ALH, and C-LCIS suggests that these lesions are associated with an elevated future breast cancer risk; therefore, patients diagnosed with these lesions should be recommended to undergo comprehensive risk assessment and counseling about breast cancer risk-reducing strategies. The magnitude of future breast cancer risk associated with P-LCIS and F-LCIS remains uncertain, yet if these lesions are determined to be hormone receptor positive, risk-reducing medications should be considered. There is no evidence that FEA is associated with an elevated future breast cancer risk. A second pathology review confirmation is recommended for ADH, should be considered for FEA, and is not necessary for ALH or LCIS. Currently available evidence supports the need to diagnostically excise most ADH, P-LCIS, and F-LCIS cases identified on core biopsy, although some ADH cases fulfilling strict criteria and multidisciplinary consensus can be observed. P-LCIS and F-LCIS require a negative margin, but ADH does not. ALH and C-LCIS can be safely observed if the core biopsy diagnosis is concordant with imaging features (ie, radiographic-pathologic concordance is established). Provided radiologic-pathologic concordance is confirmed, diagnostic excision is generally not indicated after a diagnosis of FEA alone.

CONCLUSIONS AND RELEVANCE: These guidelines provide evidence-informed, consensus-based recommendations for the management of atypical lesions of the breast, including ADH, ALH, FEA, C-LCIS, P-LCIS, and F-LCIS. Practicing clinicians who treat patients with atypical breast lesions or LCIS should consider integrating these guidelines into clinical management.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Nakhlis, Bedrosian, King, et al. American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 Guidelines for the Management of Proliferative Lesions With Atypia and Lobular Carcinoma In Situ. JAMA Surg. 2026. PMID: 42616513. doi:10.1001/jamasurg.2026.3552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。